These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

141 related items for PubMed ID: 39279018

  • 1. Efficacy and safety of tocilizumab in Chinese patients with systemic juvenile idiopathic arthritis: a multicentre phase IV trial.
    Li C, Tang X, Zhou Z, Sun L, Lu M, Zhou W, Yang S, Zheng W, Yu H, Tan W, Zhang J, Zhang Y, Kong Y, Xu J.
    Clin Rheumatol; 2024 Nov; 43(11):3457-3467. PubMed ID: 39279018
    [Abstract] [Full Text] [Related]

  • 2. Longterm safety and effectiveness of the anti-interleukin 6 receptor monoclonal antibody tocilizumab in patients with systemic juvenile idiopathic arthritis in Japan.
    Yokota S, Imagawa T, Mori M, Miyamae T, Takei S, Iwata N, Umebayashi H, Murata T, Miyoshi M, Tomiita M, Nishimoto N, Kishimoto T.
    J Rheumatol; 2014 Apr; 41(4):759-67. PubMed ID: 24634205
    [Abstract] [Full Text] [Related]

  • 3. Long-term efficacy and safety of subcutaneous tocilizumab in clinical trials of polyarticular or systemic juvenile idiopathic arthritis.
    Brunner HI, Ruperto N, Ramanan AV, Horneff G, Minden K, Calvo Penades I, Alexeeva E, Cleary G, Stern SM, Kone-Paut I, Maldonado Velázquez MDR, Rabinovich CE, Remesal A, Silva CA, Nikishina I, Zucchetto M, Brockwell L, Gordon O, Nagel S, De Benedetti F, PRINTO and PRCSG Investigators.
    Rheumatology (Oxford); 2024 Sep 01; 63(9):2535-2546. PubMed ID: 38552315
    [Abstract] [Full Text] [Related]

  • 4. Subcutaneous dosing regimens of tocilizumab in children with systemic or polyarticular juvenile idiopathic arthritis.
    Ruperto N, Brunner HI, Ramanan AV, Horneff G, Cuttica R, Henrickson M, Anton J, Boteanu AL, Penades IC, Minden K, Schmeling H, Hufnagel M, Weiss JE, Pardeo M, Nanda K, Roth J, Rubio-Pérez N, Hsu JC, Wimalasundera S, Wells C, Bharucha K, Douglass W, Bao M, Mallalieu NL, Martini A, Lovell D, Benedetti F, Paediatric Rheumatology INternational Trials Organisation (PRINTO) and the Paediatric Rheumatology Collaborative Study Group (PRCSG).
    Rheumatology (Oxford); 2021 Oct 02; 60(10):4568-4580. PubMed ID: 33506875
    [Abstract] [Full Text] [Related]

  • 5. Efficacy and Safety of Tocilizumab for Polyarticular-Course Juvenile Idiopathic Arthritis in the Open-Label Two-Year Extension of a Phase III Trial.
    Brunner HI, Ruperto N, Zuber Z, Cuttica R, Keltsev V, Xavier RM, Burgos-Vargas R, Penades IC, Silverman ED, Espada G, Zavaler MF, Kimura Y, Duarte C, Job-Deslandre C, Joos R, Douglass W, Wimalasundera S, Bharucha KN, Wells C, Lovell DJ, Martini A, de Benedetti F, Paediatric Rheumatology International Trials Organisation (PRINTO) and the Pediatric Rheumatology Collaborative Study Group (PRCSG).
    Arthritis Rheumatol; 2021 Mar 02; 73(3):530-541. PubMed ID: 32951358
    [Abstract] [Full Text] [Related]

  • 6. Long-term, interventional, open-label extension study evaluating the safety of tocilizumab treatment in patients with polyarticular-course juvenile idiopathic arthritis from Poland and Russia who completed the global, international CHERISH trial.
    Opoka-Winiarska V, Żuber Z, Alexeeva E, Chasnyk V, Nikishina I, Dębowska G, Smolewska E.
    Clin Rheumatol; 2018 Jul 02; 37(7):1807-1816. PubMed ID: 29654485
    [Abstract] [Full Text] [Related]

  • 7. Intravenous dosing of tocilizumab in patients younger than two years of age with systemic juvenile idiopathic arthritis: results from an open-label phase 1 clinical trial.
    Mallalieu NL, Wimalasundera S, Hsu JC, Douglass W, Wells C, Penades IC, Cuttica R, Huppertz HI, Joos R, Kimura Y, Milojevic D, Rosenkranz M, Schikler K, Constantin T, Wouters C.
    Pediatr Rheumatol Online J; 2019 Aug 22; 17(1):57. PubMed ID: 31438986
    [Abstract] [Full Text] [Related]

  • 8. Experience with etanercept, tocilizumab and interleukin-1 inhibitors in systemic onset juvenile idiopathic arthritis patients from the BIKER registry.
    Horneff G, Schulz AC, Klotsche J, Hospach A, Minden K, Foeldvari I, Trauzeddel R, Ganser G, Weller-Heinemann F, Haas JP.
    Arthritis Res Ther; 2017 Nov 22; 19(1):256. PubMed ID: 29166924
    [Abstract] [Full Text] [Related]

  • 9. Tocilizumab for juvenile idiopathic arthritis: a single-center case series.
    Yazılıtaş F, Özdel S, Şimşek D, Aydoğ Ö, Çakıcı EK, Can GG, Güngör T, Bülbül M.
    Sao Paulo Med J; 2019 Nov 22; 137(6):517-522. PubMed ID: 32159638
    [Abstract] [Full Text] [Related]

  • 10. Effect of tocilizumab on growth impairment in systemic juvenile idiopathic arthritis with long-term corticosteroid therapy.
    Miyamae T, Yokoya S, Yamanaka H, Yokota S.
    Mod Rheumatol; 2014 Jul 22; 24(4):567-71. PubMed ID: 24252004
    [Abstract] [Full Text] [Related]

  • 11. Efficacy and safety of canakinumab in systemic juvenile idiopathic arthritis: 48-week results from an open-label phase III study in Japanese patients.
    Nishimura K, Hara R, Umebayashi H, Takei S, Iwata N, Imagawa T, Shimizu M, Tomiita M, Seko N, Kitawaki T, Yokota S.
    Mod Rheumatol; 2021 Jan 22; 31(1):226-234. PubMed ID: 32552266
    [Abstract] [Full Text] [Related]

  • 12. Efficacy and safety of an early response-based tapering regimen of tocilizumab in children with systemic juvenile idiopathic arthritis.
    Dey S, Roy D, Sinhamahapatra P, Ghosh A.
    Int J Rheum Dis; 2024 May 22; 27(5):e15196. PubMed ID: 38769886
    [Abstract] [Full Text] [Related]

  • 13. Tocilizumab in systemic juvenile idiopathic arthritis in a real-world clinical setting: results from 1 year of postmarketing surveillance follow-up of 417 patients in Japan.
    Yokota S, Itoh Y, Morio T, Origasa H, Sumitomo N, Tomobe M, Tanaka K, Minota S.
    Ann Rheum Dis; 2016 Sep 22; 75(9):1654-60. PubMed ID: 26644233
    [Abstract] [Full Text] [Related]

  • 14. Growth During Tocilizumab Therapy for Polyarticular-course Juvenile Idiopathic Arthritis: 2-year Data from a Phase III Clinical Trial.
    Bharucha KN, Brunner HI, Calvo Penadés I, Nikishina I, Rubio-Pérez N, Oliveira S, Kobusinska K, Schmeling H, Sztajnbok F, Weller-Heinemann F, Zholobova E, Zulian F, Allen R, Chaitow J, Frane J, Wells C, Ruperto N, De Benedetti F, Paediatric Rheumatology International Trials Organisation and the Pediatric Rheumatology Collaborative Study Group.
    J Rheumatol; 2018 Aug 22; 45(8):1173-1179. PubMed ID: 29961686
    [Abstract] [Full Text] [Related]

  • 15. Efficacy and safety of tocilizumab in patients with polyarticular-course juvenile idiopathic arthritis: results from a phase 3, randomised, double-blind withdrawal trial.
    Brunner HI, Ruperto N, Zuber Z, Keane C, Harari O, Kenwright A, Lu P, Cuttica R, Keltsev V, Xavier RM, Calvo I, Nikishina I, Rubio-Pérez N, Alexeeva E, Chasnyk V, Horneff G, Opoka-Winiarska V, Quartier P, Silva CA, Silverman E, Spindler A, Baildam E, Gámir ML, Martin A, Rietschel C, Siri D, Smolewska E, Lovell D, Martini A, De Benedetti F, Paediatric Rheumatology International Trials Organisation PRINTO, Pediatric Rheumatology Collaborative Study Group (PRCSG).
    Ann Rheum Dis; 2015 Jun 22; 74(6):1110-7. PubMed ID: 24834925
    [Abstract] [Full Text] [Related]

  • 16. Comparisons of the outcomes between early and late tocilizumab treatment in systemic juvenile idiopathic arthritis.
    Pacharapakornpong T, Vallibhakara SA, Lerkvaleekul B, Vilaiyuk S.
    Rheumatol Int; 2017 Feb 22; 37(2):251-255. PubMed ID: 27798725
    [Abstract] [Full Text] [Related]

  • 17. Functional Ability and Health-Related Quality of Life in Randomized Controlled Trials of Tocilizumab in Patients With Juvenile Idiopathic Arthritis.
    Brunner HI, Chen C, Bovis F, De Benedetti F, Espada G, Joos R, Akikusa J, Chaitow J, Boteanu AL, Kimura Y, Rietschel C, Siri D, Smolewska E, Schmeling H, Brown DE, Martini A, Lovell DJ, Huang B, Ruperto N, Paediatric Rheumatology International Trials Organisation and the Pediatric Rheumatology Collaborative Study Group.
    Arthritis Care Res (Hoboken); 2021 Sep 22; 73(9):1264-1274. PubMed ID: 32702212
    [Abstract] [Full Text] [Related]

  • 18. Randomized trial of tocilizumab in systemic juvenile idiopathic arthritis.
    De Benedetti F, Brunner HI, Ruperto N, Kenwright A, Wright S, Calvo I, Cuttica R, Ravelli A, Schneider R, Woo P, Wouters C, Xavier R, Zemel L, Baildam E, Burgos-Vargas R, Dolezalova P, Garay SM, Merino R, Joos R, Grom A, Wulffraat N, Zuber Z, Zulian F, Lovell D, Martini A, PRINTO, PRCSG.
    N Engl J Med; 2012 Dec 20; 367(25):2385-95. PubMed ID: 23252525
    [Abstract] [Full Text] [Related]

  • 19. Intravenous abatacept in Japanese patients with polyarticular-course juvenile idiopathic arthritis: results from a phase III open-label study.
    Hara R, Umebayashi H, Takei S, Okamoto N, Iwata N, Yamasaki Y, Nakagishi Y, Kizawa T, Kobayashi I, Imagawa T, Kinjo N, Amano N, Takahashi Y, Mori M, Itoh Y, Yokota S.
    Pediatr Rheumatol Online J; 2019 Apr 30; 17(1):17. PubMed ID: 31039807
    [Abstract] [Full Text] [Related]

  • 20. Safety of tocilizumab in the treatment of juvenile idiopathic arthritis.
    Machado SH, Xavier RM.
    Expert Opin Drug Saf; 2017 Apr 30; 16(4):493-500. PubMed ID: 28277841
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.